Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/51593 |
Resumo: | Programa Brasileiro de DST-AIDS e Hepatites Virais. UNODC. Laboratório de Pesquisa Clínica em Micobactérias do INI, FIOCRUZ. Intramural Research Programa da Fundação Oswaldo Cruz. Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). Coordenação de Aperfeiçoamento de Pessoal de Ńivel Superior (CAPES) |
| id |
CRUZ_f8f1929a5d538c9b86f45edacf4000a4 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/51593 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Sant´Anna, Flávia M.Pereira, Mariana AraújoSchmaltz, Carolina A. S.Arriaga, María B.Oliveira, Raquel V. C. deAndrade, Bruno B.Rolla, Valeria C.2022-03-07T16:59:33Z2022-03-07T16:59:33Z2022SANT´ANNA, Flávia M. et al. Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study. Frontiers in Tropical Diseases, v. 2, p. 1-11, Jan. 2022.2673-7515https://www.arca.fiocruz.br/handle/icict/5159310.3389/fitd.2021.748310Programa Brasileiro de DST-AIDS e Hepatites Virais. UNODC. Laboratório de Pesquisa Clínica em Micobactérias do INI, FIOCRUZ. Intramural Research Programa da Fundação Oswaldo Cruz. Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). Coordenação de Aperfeiçoamento de Pessoal de Ńivel Superior (CAPES)Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Programa de Pós-Graduação em Pesquisa Clínica em Doenças Infecciosas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobactérias. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil / Universidade Federal da Bahia. Escola de Medicina. Salvador, BA, Brasil / Iniciativa de Pesquisa Translacional e Epidemiológica da Rede de Organizações Multinacionais. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobactérias. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil / Universidade Federal da Bahia. Escola de Medicina. Salvador, BA, Brasil / Iniciativa de Pesquisa Translacional e Epidemiológica da Rede de Organizações Multinacionais. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Programa de Pós-Graduação em Pesquisa Clínica em Doenças Infecciosas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Epidemiologia Clínica. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil / Universidade Federal da Bahia. Escola de Medicina. Salvador, BA, Brasil / Iniciativa de Pesquisa Translacional e Epidemiológica da Rede de Organizações Multinacionais. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Curso de Medicina. Salvador, BA, Brasil / Universidade Salvador. Curso de Medicina. Laureate Universities. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Programa de Pós-Graduação em Pesquisa Clínica em Doenças Infecciosas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobactérias. Rio de Janeiro, RJ, Brasil.Standard anti-tuberculosis treatment is highly effective, but a great challenge is the management of adverse drug reactions (ADR). Our study aimed to characterize ADR according to type, severity and time of occurrence. A prospective tuberculosis (TB) cohort has been followed, from 2010 to 2016, at a reference center in Rio de Janeiro, Brazil. Clinical and laboratory tests information were collected in all visits. ADR were described according to the affected organ/system, classified as clinical and/or laboratory, early (first 2 months) or late. ADR’s causality and intensity were assessed. In our study 552 patients were included, 78.8% presented at least one ADR, 34% were people living with HIV (PLHIV). Most ADR were clinical (53%), early (82.5%), mild/moderate (88.7%) events and of “metabolic annutritional disorders” category. There were no significant differences in type, severity or causality between “early” and “late” groups. However, “early” group presented a higher frequency of “metabolic and nutritional disorders” (27.8%) and “gastrointestinal system disorders” (23.5%), while “skin and appendages disorders” were more frequent in the “late” group. ADR are frequent and occur at any time during treatment, although the majority are early and grade and not severe.engFrontiers MediaTuberculoseToxicidadeAntituberculososTuberculosisToxicityAntitubercular AgentsTuberculosisToxicidadAntituberculososTuberculoseToxicitéAntituberculeuxAdverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/51593/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALSant'Anna, F.M. Adverse Drug Reactions....pdfSant'Anna, F.M. Adverse Drug Reactions....pdfapplication/pdf2877354https://www.arca.fiocruz.br/bitstream/icict/51593/2/Sant%27Anna%2c%20%20F.M.%20Adverse%20Drug%20Reactions....pdf526d725357e876e66b520fee21858278MD52icict/515932023-03-15 14:33:13.196oai:www.arca.fiocruz.br:icict/51593Q0VTU8ODTyBOw4NPIEVYQ0xVU0lWQSBERSBESVJFSVRPUyBBVVRPUkFJUwoKQW8gYWNlaXRhciBvcyBURVJNT1MgZSBDT05EScOHw5VFUyBkZXN0YSBDRVNTw4NPLCBvIEFVVE9SIGUvb3UgVElUVUxBUiBkZSBkaXJlaXRvcwphdXRvcmFpcyBzb2JyZSBhIE9CUkEgZGUgcXVlIHRyYXRhIGVzdGUgZG9jdW1lbnRvOgoKKDEpIENFREUgZSBUUkFOU0ZFUkUsIHRvdGFsIGUgZ3JhdHVpdGFtZW50ZSwgw6AgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaLCBlbQpjYXLDoXRlciBwZXJtYW5lbnRlLCBpcnJldm9nw6F2ZWwgZSBOw4NPIEVYQ0xVU0lWTywgdG9kb3Mgb3MgZGlyZWl0b3MgcGF0cmltb25pYWlzIE7Dg08KQ09NRVJDSUFJUyBkZSB1dGlsaXphw6fDo28gZGEgT0JSQSBhcnTDrXN0aWNhIGUvb3UgY2llbnTDrWZpY2EgaW5kaWNhZGEgYWNpbWEsIGluY2x1c2l2ZSBvcyBkaXJlaXRvcwpkZSB2b3ogZSBpbWFnZW0gdmluY3VsYWRvcyDDoCBPQlJBLCBkdXJhbnRlIHRvZG8gbyBwcmF6byBkZSBkdXJhw6fDo28gZG9zIGRpcmVpdG9zIGF1dG9yYWlzLCBlbQpxdWFscXVlciBpZGlvbWEgZSBlbSB0b2RvcyBvcyBwYcOtc2VzOwoKKDIpIEFDRUlUQSBxdWUgYSBjZXNzw6NvIHRvdGFsIG7Do28gZXhjbHVzaXZhLCBwZXJtYW5lbnRlIGUgaXJyZXZvZ8OhdmVsIGRvcyBkaXJlaXRvcyBhdXRvcmFpcwpwYXRyaW1vbmlhaXMgbsOjbyBjb21lcmNpYWlzIGRlIHV0aWxpemHDp8OjbyBkZSBxdWUgdHJhdGEgZXN0ZSBkb2N1bWVudG8gaW5jbHVpLCBleGVtcGxpZmljYXRpdmFtZW50ZSwKb3MgZGlyZWl0b3MgZGUgZGlzcG9uaWJpbGl6YcOnw6NvIGUgY29tdW5pY2HDp8OjbyBww7pibGljYSBkYSBPQlJBLCBlbSBxdWFscXVlciBtZWlvIG91IHZlw61jdWxvLAppbmNsdXNpdmUgZW0gUmVwb3NpdMOzcmlvcyBEaWdpdGFpcywgYmVtIGNvbW8gb3MgZGlyZWl0b3MgZGUgcmVwcm9kdcOnw6NvLCBleGliacOnw6NvLCBleGVjdcOnw6NvLApkZWNsYW1hw6fDo28sIHJlY2l0YcOnw6NvLCBleHBvc2nDp8OjbywgYXJxdWl2YW1lbnRvLCBpbmNsdXPDo28gZW0gYmFuY28gZGUgZGFkb3MsIHByZXNlcnZhw6fDo28sIGRpZnVzw6NvLApkaXN0cmlidWnDp8OjbywgZGl2dWxnYcOnw6NvLCBlbXByw6lzdGltbywgdHJhZHXDp8OjbywgZHVibGFnZW0sIGxlZ2VuZGFnZW0sIGluY2x1c8OjbyBlbSBub3ZhcyBvYnJhcyBvdQpjb2xldMOibmVhcywgcmV1dGlsaXphw6fDo28sIGVkacOnw6NvLCBwcm9kdcOnw6NvIGRlIG1hdGVyaWFsIGRpZMOhdGljbyBlIGN1cnNvcyBvdSBxdWFscXVlciBmb3JtYSBkZQp1dGlsaXphw6fDo28gbsOjbyBjb21lcmNpYWw7CgooMykgUkVDT05IRUNFIHF1ZSBhIGNlc3PDo28gYXF1aSBlc3BlY2lmaWNhZGEgY29uY2VkZSDDoCBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPCkNSVVogbyBkaXJlaXRvIGRlIGF1dG9yaXphciBxdWFscXVlciBwZXNzb2Eg4oCTIGbDrXNpY2Egb3UganVyw61kaWNhLCBww7pibGljYSBvdSBwcml2YWRhLCBuYWNpb25hbCBvdQplc3RyYW5nZWlyYSDigJMgYSBhY2Vzc2FyIGUgdXRpbGl6YXIgYW1wbGFtZW50ZSBhIE9CUkEsIHNlbSBleGNsdXNpdmlkYWRlLCBwYXJhIHF1YWlzcXVlcgpmaW5hbGlkYWRlcyBuw6NvIGNvbWVyY2lhaXM7CgooNCkgREVDTEFSQSBxdWUgYSBvYnJhIMOpIGNyaWHDp8OjbyBvcmlnaW5hbCBlIHF1ZSDDqSBvIHRpdHVsYXIgZG9zIGRpcmVpdG9zIGFxdWkgY2VkaWRvcyBlIGF1dG9yaXphZG9zLApyZXNwb25zYWJpbGl6YW5kby1zZSBpbnRlZ3JhbG1lbnRlIHBlbG8gY29udGXDumRvIGUgb3V0cm9zIGVsZW1lbnRvcyBxdWUgZmF6ZW0gcGFydGUgZGEgT0JSQSwKaW5jbHVzaXZlIG9zIGRpcmVpdG9zIGRlIHZveiBlIGltYWdlbSB2aW5jdWxhZG9zIMOgIE9CUkEsIG9icmlnYW5kby1zZSBhIGluZGVuaXphciB0ZXJjZWlyb3MgcG9yCmRhbm9zLCBiZW0gY29tbyBpbmRlbml6YXIgZSByZXNzYXJjaXIgYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVogZGUKZXZlbnR1YWlzIGRlc3Blc2FzIHF1ZSB2aWVyZW0gYSBzdXBvcnRhciwgZW0gcmF6w6NvIGRlIHF1YWxxdWVyIG9mZW5zYSBhIGRpcmVpdG9zIGF1dG9yYWlzIG91CmRpcmVpdG9zIGRlIHZveiBvdSBpbWFnZW0sIHByaW5jaXBhbG1lbnRlIG5vIHF1ZSBkaXogcmVzcGVpdG8gYSBwbMOhZ2lvIGUgdmlvbGHDp8O1ZXMgZGUgZGlyZWl0b3M7CgooNSkgQUZJUk1BIHF1ZSBjb25oZWNlIGEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTwpPU1dBTERPIENSVVogZSBhcyBkaXJldHJpemVzIHBhcmEgbyBmdW5jaW9uYW1lbnRvIGRvIHJlcG9zaXTDs3JpbyBpbnN0aXR1Y2lvbmFsIEFSQ0EuCgpBIFBvbMOtdGljYSBJbnN0aXR1Y2lvbmFsIGRlIEFjZXNzbyBBYmVydG8gZGEgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaIHJlc2VydmEKZXhjbHVzaXZhbWVudGUgYW8gQVVUT1Igb3MgZGlyZWl0b3MgbW9yYWlzIGUgb3MgdXNvcyBjb21lcmNpYWlzIHNvYnJlIGFzIG9icmFzIGRlIHN1YSBhdXRvcmlhCmUvb3UgdGl0dWxhcmlkYWRlLCBzZW5kbyBvcyB0ZXJjZWlyb3MgdXN1w6FyaW9zIHJlc3BvbnPDoXZlaXMgcGVsYSBhdHJpYnVpw6fDo28gZGUgYXV0b3JpYSBlIG1hbnV0ZW7Dp8OjbwpkYSBpbnRlZ3JpZGFkZSBkYSBPQlJBIGVtIHF1YWxxdWVyIHV0aWxpemHDp8Ojby4KCkEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVoKcmVzcGVpdGEgb3MgY29udHJhdG9zIGUgYWNvcmRvcyBwcmVleGlzdGVudGVzIGRvcyBBdXRvcmVzIGNvbSB0ZXJjZWlyb3MsIGNhYmVuZG8gYW9zIEF1dG9yZXMKaW5mb3JtYXIgw6AgSW5zdGl0dWnDp8OjbyBhcyBjb25kacOnw7VlcyBlIG91dHJhcyByZXN0cmnDp8O1ZXMgaW1wb3N0YXMgcG9yIGVzdGVzIGluc3RydW1lbnRvcy4KRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:33:13Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study |
| title |
Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study |
| spellingShingle |
Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study Sant´Anna, Flávia M. Tuberculose Toxicidade Antituberculosos Tuberculosis Toxicity Antitubercular Agents Tuberculosis Toxicidad Antituberculosos Tuberculose Toxicité Antituberculeux |
| title_short |
Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study |
| title_full |
Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study |
| title_fullStr |
Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study |
| title_full_unstemmed |
Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study |
| title_sort |
Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study |
| author |
Sant´Anna, Flávia M. |
| author_facet |
Sant´Anna, Flávia M. Pereira, Mariana Araújo Schmaltz, Carolina A. S. Arriaga, María B. Oliveira, Raquel V. C. de Andrade, Bruno B. Rolla, Valeria C. |
| author_role |
author |
| author2 |
Pereira, Mariana Araújo Schmaltz, Carolina A. S. Arriaga, María B. Oliveira, Raquel V. C. de Andrade, Bruno B. Rolla, Valeria C. |
| author2_role |
author author author author author author |
| dc.contributor.author.fl_str_mv |
Sant´Anna, Flávia M. Pereira, Mariana Araújo Schmaltz, Carolina A. S. Arriaga, María B. Oliveira, Raquel V. C. de Andrade, Bruno B. Rolla, Valeria C. |
| dc.subject.other.pt_BR.fl_str_mv |
Tuberculose Toxicidade Antituberculosos |
| topic |
Tuberculose Toxicidade Antituberculosos Tuberculosis Toxicity Antitubercular Agents Tuberculosis Toxicidad Antituberculosos Tuberculose Toxicité Antituberculeux |
| dc.subject.en.pt_BR.fl_str_mv |
Tuberculosis Toxicity Antitubercular Agents |
| dc.subject.es.pt_BR.fl_str_mv |
Tuberculosis Toxicidad Antituberculosos |
| dc.subject.fr.pt_BR.fl_str_mv |
Tuberculose Toxicité Antituberculeux |
| description |
Programa Brasileiro de DST-AIDS e Hepatites Virais. UNODC. Laboratório de Pesquisa Clínica em Micobactérias do INI, FIOCRUZ. Intramural Research Programa da Fundação Oswaldo Cruz. Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). Coordenação de Aperfeiçoamento de Pessoal de Ńivel Superior (CAPES) |
| publishDate |
2022 |
| dc.date.accessioned.fl_str_mv |
2022-03-07T16:59:33Z |
| dc.date.available.fl_str_mv |
2022-03-07T16:59:33Z |
| dc.date.issued.fl_str_mv |
2022 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
SANT´ANNA, Flávia M. et al. Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study. Frontiers in Tropical Diseases, v. 2, p. 1-11, Jan. 2022. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/51593 |
| dc.identifier.issn.pt_BR.fl_str_mv |
2673-7515 |
| dc.identifier.doi.pt_BR.fl_str_mv |
10.3389/fitd.2021.748310 |
| identifier_str_mv |
SANT´ANNA, Flávia M. et al. Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study. Frontiers in Tropical Diseases, v. 2, p. 1-11, Jan. 2022. 2673-7515 10.3389/fitd.2021.748310 |
| url |
https://www.arca.fiocruz.br/handle/icict/51593 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Frontiers Media |
| publisher.none.fl_str_mv |
Frontiers Media |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/51593/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/51593/2/Sant%27Anna%2c%20%20F.M.%20Adverse%20Drug%20Reactions....pdf |
| bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 526d725357e876e66b520fee21858278 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1798324788189462528 |